Showing results (71-80 of 97) with videos related to

Sort By:
Pageof 10
British Journal of Haematology|September 16, 2022
Daratumumab plus lenalidomide, bortezomib and dexamethasone in newly diagnosed multiple myeloma: Analysis of vascular thrombotic events in the GRIFFIN studyDouglas W Sborov, Muhamed Baljevic, Brandi Reeves, et al.
Clinical Lymphoma, Myeloma & Leukemia|May 13, 2025
Daratumumab for newly diagnosed multiple myeloma: Pooled analysis of patients aged ≥65 years from GRIFFIN and PERSEUSPaula Rodriguez-Otero, Peter M Voorhees, Mario Boccadoro, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 9, 2015
A Phase II Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1/2 Inhibitor, in Relapsed/Refractory Multiple MyelomaBeata Holkova, Adriana Zingone, Maciej Kmieciak, et al.
Blood|January 1, 2005
Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignanciesRobert Z Orlowski, Peter M Voorhees, Reynaldo A Garcia, et al.
American Journal of Hematology|April 16, 2024
Health-related quality of life in transplant-eligible patients with newly diagnosed multiple myeloma treated with daratumumab, lenalidomide, bortezomib, and dexamethasone: Patient-reported outcomes from GRIFFINRebecca Silbermann, Jacob Laubach, Jonathan L Kaufman, et al.
Blood Cancer Journal|July 8, 2024
Daratumumab in transplant-eligible patients with newly diagnosed multiple myeloma: final analysis of clinically relevant subgroups in GRIFFINAjai Chari, Jonathan L Kaufman, Jacob Laubach, et al.
The Lancet. Haematology|September 14, 2023
Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trialPeter M Voorhees, Douglas W Sborov, Jacob Laubach, et al.
Blood|April 24, 2020
Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trialPeter M Voorhees, Jonathan L Kaufman, Jacob Laubach, et al.
Blood Cancer Journal|August 9, 2023
Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapyChristopher J Ferreri, Michelle A T Hildebrandt, Hamza Hashmi, et al.
Lancet (London, England)|January 19, 2016
Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trialSagar Lonial, Brendan M Weiss, Saad Z Usmani, et al.
Pageof 10